2019 Press Releases


Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
January 28, 2019
Xenon Provides Key Regulatory Updates on XEN007 and XEN1101
FDA Grants Rare Pediatric Disease Designation to XEN007 for Alternating Hemiplegia of Childhood (AHC); Xenon Eligible to Apply for Priority Review Voucher IND for XEN1101 Accepted; Site Selection and Patient Enrollment Underway in Canada and the United States for XEN1101 Phase 2b Clinical Trial ... More >>
January 6, 2019
Xenon Pharmaceuticals Outlines 2019 Key Milestones
Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 BURNABY, British Columbia, Jan. 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provide... More >>